Aldeyra Therapeutics (ALDX) vs Talphera (TLPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Talphera (TLPH) has outperformed Aldeyra Therapeutics (ALDX) over the past year, losing 18.2% versus a loss of 83.1%. Over five years, ALDX leads with a -88.6% price change compared with -94.7% for TLPH. Aldeyra Therapeutics is the larger company by market cap ($57.2 million vs $56.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALDX | TLPH |
|---|---|---|
| Share price | $0.9477 | $1.08 |
| Market cap | $57.17M | $56.06M |
| 1-day change | -1.14% | +2.86% |
| YTD return | -81.70% | -5.26% |
| 1-year return | -83.14% | -18.18% |
| 5-year return | -88.64% | -94.71% |
| EPS (TTM) | $-0.38 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.93 | $1.57 |
| 52-week low | $0.862 | $0.69 |
| Distance from 52-week high | -84.02% | -31.21% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +596.42% | +189.81% |
| Average volume | 1.18M | 238.38K |
| Shares outstanding | 60.33M | 51.91M |
| Employees | 6 | 12 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLPH has outperformed ALDX by 65.0 percentage points over the past year.
About Aldeyra Therapeutics
ALDX stock →Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
Healthcare · Biotechnology · 6 employees
About Talphera
TLPH stock →Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
Healthcare · Drug Manufacturers - Specialty & Generic · 12 employees
ALDX vs TLPH FAQ
Which is bigger, Aldeyra Therapeutics or Talphera?
Aldeyra Therapeutics (ALDX) is larger, with a market capitalization of $57.17M compared with $56.06M for Talphera (TLPH).
Which stock has performed better over the past year, ALDX or TLPH?
TLPH returned -18.18% over the past 12 months, compared with -83.14% for ALDX (price return, excluding dividends). Past performance does not predict future results.
Are Aldeyra Therapeutics and Talphera in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Aldeyra Therapeutics and Drug Manufacturers - Specialty & Generic for Talphera.